Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Cash & Equivalents (2021 - 2025)

Bioregenx has reported Cash & Equivalents over the past 5 years, most recently at $69383.0 for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 18.8% year-over-year to $69383.0; the TTM value through Dec 2025 reached $69383.0, up 18.8%, while the annual FY2025 figure was $69383.0, 18.8% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $69383.0 at Bioregenx, up from $46947.0 in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $125402.0 in Q4 2023 and troughed at $676.0 in Q4 2022.
  • A 5-year average of $46983.0 and a median of $46947.0 in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: plummeted 97.22% in 2022 and later soared 18450.59% in 2023.
  • Year by year, Cash & Equivalents stood at $24358.0 in 2021, then plummeted by 97.22% to $676.0 in 2022, then soared by 18450.59% to $125402.0 in 2023, then plummeted by 53.43% to $58404.0 in 2024, then rose by 18.8% to $69383.0 in 2025.
  • Business Quant data shows Cash & Equivalents for BRGX at $69383.0 in Q4 2025, $46947.0 in Q3 2025, and $46456.0 in Q2 2025.